Protara Therapeutics Stock Today
| TARA Stock | USD 4.62 0.09 1.91% |
PerformanceVery Weak
| Odds Of DistressLow
|
Protara Therapeutics is trading at 4.62 as of the 21st of March 2025, a 1.91 percent decrease since the beginning of the trading day. The stock's open price was 4.71. Protara Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of October 2014 | Category Healthcare | Classification Health Care |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. The company has 36.77 M outstanding shares of which 4.15 M shares are at this time shorted by private and institutional investors with about 9.85 trading days to cover. More on Protara Therapeutics
Moving together with Protara Stock
Moving against Protara Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Protara Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Jakarta Stock Exchange, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProtara Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protara Therapeutics' financial leverage. It provides some insight into what part of Protara Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Protara Therapeutics (TARA) is traded on NASDAQ Exchange in USA. It is located in 345 Park Avenue South, New York, NY, United States, 10010 and employs 28 people. Protara Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 173.17 M. Protara Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.77 M outstanding shares of which 4.15 M shares are at this time shorted by private and institutional investors with about 9.85 trading days to cover.
Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Protara Therapeutics Probability Of Bankruptcy
Ownership AllocationProtara Therapeutics owns a total of 36.77 Million outstanding shares. The majority of Protara Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Protara Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Protara Therapeutics. Please pay attention to any change in the institutional holdings of Protara Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Protara Ownership Details
Protara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-12-31 | 1 M | |
| Woodline Partners Lp | 2024-12-31 | 853.2 K | |
| Boxer Capital Llc | 2024-09-30 | 811.6 K | |
| 5am Venture Management, Llc | 2024-12-31 | 800 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 536.8 K | |
| Driehaus Capital Management Llc | 2024-12-31 | 517.2 K | |
| Millennium Management Llc | 2024-12-31 | 371.5 K | |
| Superstring Capital Management Lp | 2024-12-31 | 360 K | |
| Ikarian Capital, Llc | 2024-12-31 | 350.5 K | |
| Ra Capital Management, Llc | 2024-12-31 | 3.4 M | |
| Hhg Plc | 2024-12-31 | 2.3 M |
Protara Therapeutics Historical Income Statement
Protara Stock Against Markets
Protara Therapeutics Corporate Management
| MBA MPH | VP CoFounder | Profile | |
| Jesse Shefferman | Principal CoFounder | Profile | |
| Jathin MD | Executive Officer | Profile | |
| Justine OMalley | Senior Affairs | Profile | |
| Kristine Rosse | VP Officer | Profile | |
| Patrick MBA | Chief Officer | Profile | |
| Mary JD | General Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.